Azitra, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Azitra, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $215.95K.
- Azitra, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $2.85M, a 68.58% decline year-over-year.
- Azitra, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $694.31K.
- Azitra, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $9.06M.
- Azitra, Inc. stock issued during period, value, new issues for fiscal 2025 was $5.94M.
- Azitra, Inc. stock issued during period, value, new issues for fiscal 2023 was $5.99M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $215.95K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $5.94M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $2.85M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $694.31K 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $9.06M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $4.29M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $5.99M 10-K · filed 2025-02-24 | |
| 2023-06-30 | $5.99M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |